V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220022091 | 220008473 | 1.7 | 61 | Adjuvant (A) | 2014-07-28 | 2014-07-28 | UKALL14- Intens/CNS Proph | 02 | N | 220032108 | UKALL2014 |
| 220022092 | 220008495 | 1.75 | 108 | Curative (C) | 2014-05-03 | 2015-03-29 | PACLITAXEL | N | N | 220032156 | PACLITAXEL |
| 220022093 | 220008506 | null | 60.1 | Curative (C) | 2014-09-03 | 2014-09-03 | Irinotecan + Modified De Gramont | N | N | 220032159 | PONATINIB |
| 220022094 | 220008586 | 1.59 | 76 | Curative (C) | null | 2017-05-01 | Thalidomide 100mg | N | N | 220032405 | UKALL60+ |
| 220022095 | 220008624 | 1.64 | 57.1 | Curative (C) | 2016-05-16 | 2016-10-19 | PERTUZUMAB + TRASTUZUMAB | N | N | 220032532 | CYCLOPHOSHAMIDE |
| 220022096 | 220008770 | 1.78 | 71.8 | Curative (C) | 2017-05-22 | 2017-06-19 | CHOP R - 14 days | N | N | 220032973 | CAPECITABINE + OXALIPLATIN |
| 220022097 | 220018058 | 1.45 | 80.5 | Disease modification (D) | 2017-06-20 | 2017-06-27 | LIPOSOMAL CYTARABINE | 2 | N | 220033250 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 220022098 | 220014790 | 1.62 | 72.1 | Curative (C) | 2015-08-21 | 2018-01-26 | Cisplatin + Etoposide (3 day) | 01 | Y | 220033807 | EOX |
| 220022099 | 220008970 | 1.64 | 81 | Palliative (P) | 2018-11-20 | 2018-12-06 | MA (Cytarabine 3g/m2) | 2 | N | 220033808 | ALL INTERIM GUIDELINES |
| 220022100 | 220009013 | null | null | Curative (C) | 2017-04-11 | 2017-04-11 | METHOTREXATE + PEGASPARGASE | 02 | null | 220033965 | CLOFARABINE + DAUNORUBICIN |
| 220022101 | 220009024 | 1.67 | 74.4 | null | 2015-01-02 | 2015-04-30 | Topotecan (intravenous) | 02 | N | 220033988 | INTERFERON |
| 220022102 | 220009062 | 1.73 | 60 | Curative (C) | 2017-05-26 | 2017-07-03 | CLOFARABINE + CYCLO + CYTARABINE + ETOP | 2 | N | 220034115 | ETOPOSIDE |
| 220022103 | 220014864 | 1.59 | null | Curative (C) | 2015-06-25 | 2015-06-25 | IPO | N | N | 220034334 | FLUOROURACIL |
| 220022104 | 220009137 | 1.74 | 78.4 | Palliative (P) | 2019-05-28 | 2019-06-05 | FIGARO TRIAL | N | N | 220034424 | TRASTUZUMAB |
| 220022105 | 220009162 | 1.57 | 43.1 | Curative (C) | 2015-05-13 | 2015-05-14 | INTERFERON | N | N | 220034495 | INTERFERON |
| 220022107 | 220014964 | 1.57 | 113.9 | Curative (C) | 2013-06-17 | 2013-09-15 | DA-EPOCH-R | N | null | 220035347 | LENALIDOMIDE |
| 220022108 | 220009375 | 1.67 | 76.1 | Disease modification (D) | 2015-07-23 | 2016-06-03 | Pemetrexed | N | N | 220035412 | VINCRISTINE |
| 220022110 | 220009410 | null | null | Curative (C) | 2015-12-04 | 2015-12-12 | Methotrexate High Dose (3g/m2) | null | null | 220035549 | CETUXIMAB + CISPLATIN + FU |
| 220022111 | 220015003 | 1.82 | 120 | Disease modification (D) | 2016-05-29 | 2016-05-29 | DOCETAXEL + GEMCITABINE | N | null | 220035672 | METHOTREXATE HIGH DOSE |
| 220022112 | 220015027 | null | 64.7 | Curative (C) | 2017-09-03 | 2017-12-08 | Cladribine IV (5 day) | 2 | N | 220035947 | EOF |
| 220022113 | 220009500 | 1.56 | 89.6 | Disease modification (D) | 2016-04-17 | 2016-04-17 | Capecitabine + Oxaliplatin 21day | N | null | 220036062 | ARSENIC TRIOXIDE |
| 220022114 | 220009512 | 1.6 | null | Disease modification (D) | 2016-05-20 | 2016-06-28 | Ipilimumab | N | N | 220036121 | DACARBAZINE |
| 220022115 | 220009581 | 1.55 | 113.1 | Disease modification (D) | 2018-08-17 | 2018-08-17 | Cetuximab 7 day (Cycle 1) | N | N | 220036432 | SPANISH MAINTENANCE |
| 220022117 | 220015092 | 1.8 | null | Curative (C) | null | 2015-02-13 | Epirubicin | N | N | 220036606 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220022118 | 220009644 | 1.9 | 93.6 | Curative (C) | 2015-06-21 | 2015-06-21 | FIGARO TRIAL | 02 | N | 220036641 | LIPOSOMAL DOXORUBICIN |
| 220022119 | 220009692 | null | 71.8 | null | 2018-02-06 | 2018-02-07 | Sorafenib | N | N | 220004682 | MITOXANTRONE + TRETINOIN |
| 220022120 | 220015122 | 1.66 | 69 | Curative (C) | 2019-07-04 | 2019-07-08 | MA (Cytarabine 3g/m2) | N | N | 220014128 | ALL INTERIM GUIDELINES |
| 220022121 | 220015127 | 1.72 | 102.4 | Curative (C) | null | 2019-04-19 | Topotecan (oral) | 2 | N | 220018242 | GEMCITABINE |
| 220022124 | 220004351 | 0 | 77.2 | Palliative (P) | 2014-01-18 | 2014-06-16 | IMATINIB | null | N | 220007267 | IMATINIB |
| 220022125 | 220004370 | 1.55 | null | Disease modification (D) | 2013-12-12 | 2014-01-25 | IMATINIB | 2 | N | 220007789 | IMATINIB |
| 220022126 | 220004406 | 0 | 73.6 | Neo-adjuvant (N) | 2016-03-20 | 2016-03-24 | IMATINIB | 02 | N | 220008562 | IMATINIB |
| 220022128 | 220004460 | 1.73 | null | Palliative (P) | 2016-05-12 | 2016-05-13 | Azacitidine | Y | N | 220009894 | AZACITIDINE |
| 220022129 | 220004489 | 1.75 | 71.8 | Palliative (P) | 2016-02-19 | 2017-10-26 | Azacitidine | N | N | 220010668 | AZACITIDINE |
| 220022130 | 220004504 | 1.61 | 40 | Curative (C) | 2014-09-26 | 2014-10-01 | DA 3+8 | N | N | 220010889 | DA |
| 220022131 | 220012388 | 1.79 | 87.5 | Curative (C) | 2017-01-22 | 2017-03-07 | CYTARABINE + DAUNORUBICIN | N | N | 220011747 | DA |
| 220022132 | 220004592 | 1.7 | 66 | Curative (C) | 2018-01-13 | 2018-01-13 | Azacitidine | N | null | 220012841 | AZACITIDINE |
| 220022133 | 220004624 | 1.75 | 106.6 | Curative (C) | 2017-09-13 | 2017-09-17 | Cytarabine High Dose | N | null | 220013701 | CYTARABINE HIGH DOSE |
| 220022134 | 220004675 | 1.65 | 99.7 | Curative (C) | 2018-05-30 | 2018-05-30 | Cytarabine High Dose | null | null | 220015129 | CYTARABINE HIGH DOSE |
| 220022135 | 220004686 | 1.68 | 79.9 | Curative (C) | 2018-09-04 | 2018-09-12 | Cytarabine High Dose | N | N | 220015369 | CYTARABINE HIGH DOSE |
| 220022138 | 220004959 | null | 77.7 | Curative (C) | 2016-06-22 | 2016-06-23 | AML17 TRIAL | 02 | N | 220019862 | AML17 TRIAL |
| 220022139 | 220019298 | 1.66 | 60 | Palliative (P) | 2019-07-05 | 2019-10-05 | AML17 TRIAL | N | N | 220019873 | AML17 TRIAL |
| 220022140 | 220004997 | 1.58 | 73 | Disease modification (D) | 2016-03-14 | 2016-08-14 | FLAG + Idarubicin | N | N | 220019939 | FLAG + IDARUBICIN |
| 220022141 | 220005061 | 1.77 | 73.5 | Adjuvant (A) | 2017-10-13 | 2017-11-16 | AML17 TRIAL | Y | N | 220020111 | AML17 TRIAL |
| 220022142 | 220005086 | 1.7 | 69.4 | Curative (C) | 2017-10-22 | 2017-10-26 | AML17 TRIAL | N | null | 220020158 | AML17 TRIAL |
| 220022143 | 220005093 | 1.74 | 71.1 | Curative (C) | 2018-06-27 | 2018-07-16 | AML17 TRIAL | 02 | N | 220020160 | AML17 TRIAL |
| 220022144 | 220005209 | 1.7 | 62.2 | Curative (C) | 2018-02-15 | 2018-03-26 | AML17 TRIAL | N | N | 220020414 | AML17 TRIAL |
| 220022145 | 220005219 | 1.57 | 98 | Disease modification (D) | 2017-09-02 | 2017-11-16 | FLAG + Idarubicin | N | N | 220020435 | FLAG + IDARUBICIN |
| 220022148 | 220005277 | 1.77 | 66.75 | Curative (C) | 2016-11-10 | 2016-12-12 | AML 19 TRIAL | Y | N | 220020503 | AML19 TRIAL |
| 220022149 | 220005296 | 1.88 | null | Disease modification (D) | 2019-03-18 | 2019-06-15 | Trial Unspecified | 01 | N | 220020551 | TRIAL |
| 220022150 | 220005316 | 1.67 | 88.4 | null | 2014-06-08 | 2014-06-09 | AML 19 TRIAL | 2 | null | 220020591 | AML19 TRIAL |